Document is current
Any future updates will be listed below
-
Authors
Miesbach, Wolfgang
Mulders, Greta
Breederveld, Daan
Pinachyan, Karen
Le Quellec, Sandra
Pabinger, Ingrid
-
Funding
Funding for this research was provided by:
CSL Behring GmbH (CSL Behring GmbH)
- License Information
-
More Information
Article History
Received: 5 March 2024
Accepted: 30 March 2024
First Online: 13 May 2024
Declarations
:
: Not applicable.
: Not applicable.
: All faculty received consultancy fees from CSL Behring for participating in the symposium at the 27th Congress of the European Hematology Association 2022 but there were no payments for development of this manuscript. W. Miesbach has received grant/research support from Bayer, Biogen Idec, Biotest, CSL Behring, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi, Takeda, and UniQure, and consultant fees from Biogen Idec, Biotest, CSL Behring, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi, Takeda, and UniQure. G. Mulders has received grant/research support from Sobi, consultancy fees from Novo Nordisk and Biomarin, and has received speaker fees from CSL Behring. D. Breederveld has received consultancy fees from CSL Behring and is the owner of an OHS company in Amsterdam. K. Pinachyan is a full-time employee of CSL Behring. S. Le Quellec is a full-time employee of CSL Behring. I. Pabinger has received honoraria for lectures from CSL Behring, Pfizer, Roche, Sobi, Takeda and Technoclone, and consultancy fees from Biomarin, CSL Behring, Sobi and Takeda.
